Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members …

2008年5月1日 · MM-121 demonstrated potent inhibition of heregulin-induced signaling events in human cancer cell lines. When MM-121 efficacy was assessed in vivo, MM-121 showed a …

MM-121, a human anti-ErbB3 monoclonal antibody, exhibited both preventive and therapeutic effects against hypoxia-induced PH. Our study reveals, for the first time, that ErbB3 serves as …

2019年5月26日 · Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor …

2010年3月14日 · In this study, we evaluated the in vivo efficacy of a therapeutic anti-ErbB3 antibody, MM-121. We found that MM-121 effectively blocked ligand-dependent activation of …

2017年10月30日 · MM-121 (seribantumab) is a fully human monoclonal antibody designed to block tumor survival signals and enhance the anti-tumor effect of combination therapies by …

2017年10月30日 · MM-121 (seribantumab) is a fully human monoclonal antibody designed to block tumor survival signals and enhance the anti-tumor effect of combination therapies by …

2014年5月20日 · Patients were randomized 2:1 to receive MM-121 20 mg/kg every other week plus daily erlotinib at 100 mg (M) or daily erlotinib alone at 150 mg (E). The primary objective …

Seribantumab monotherapy was well tolerated with most adverse events being transient and mild to moderate (grade 1 or 2) in severity; maximum tolerated dose was not reached. The highest …

Seribantumab (formerly MM-121; SAR256212), a fully human immunoglobulin (Ig) G2 anti-HER3 monoclonal antibody, was initially developed for the treatment of solid tumors in which HER3 …